Lisinopril vs Amlodipine: Switching Between Them Safely

How These Two Drugs Lower Blood Pressure Differently

Lisinopril blocks angiotensin-converting enzyme, which prevents the formation of angiotensin II. Less angiotensin II means less arterial vasoconstriction and less aldosterone secretion. Blood vessels relax. Sodium and water retention decrease. The result is lower blood pressure through the renin-angiotensin-aldosterone system (RAAS).

Amlodipine works on a completely separate pathway. It blocks L-type calcium channels in vascular smooth muscle cells, preventing calcium influx that triggers contraction. Arterioles dilate. Peripheral vascular resistance drops. Blood pressure falls without any direct effect on the RAAS.

This mechanistic independence explains why the two drugs are so frequently combined. The 2017 ACC/AHA Hypertension Guidelines recommend initiating two-drug therapy for patients with stage 2 hypertension (BP ≥140/90 mmHg), and an ACE inhibitor plus a CCB is one of the preferred pairings. The ACCOMPLISH trial (N=11,506) demonstrated that benazepril plus amlodipine reduced cardiovascular events by 19.6% compared with benazepril plus hydrochlorothiazide 1. That trial did not test lisinopril specifically, but the class effect of ACE inhibitors makes it relevant.

One practical takeaway: because these drugs act on independent systems, switching from one to the other does not create a pharmacologic "gap." The incoming drug does not need the outgoing drug's receptor to be cleared first.

What the Major Trials Tell Us About Each Drug

No large randomized trial has directly compared lisinopril to amlodipine head-to-head as monotherapy for cardiovascular outcomes. The two largest trials positioned each drug against a different comparator, and we can triangulate from those results.

ALLHAT (2002) randomized 33,357 high-risk hypertensive patients aged 55 and older to chlorthalidone, amlodipine, or lisinopril. The primary outcome (fatal coronary heart disease or nonfatal myocardial infarction) did not differ between groups. Lisinopril, however, carried a 15% higher relative risk of stroke (RR 1.15 to 95% CI 1.02 to 1.30) and a 10% higher risk of combined cardiovascular disease compared to chlorthalidone. Amlodipine matched chlorthalidone on every primary and secondary endpoint except heart failure, where amlodipine showed a modest excess [2].

ASCOT-BPLA (2005) assigned 19,257 hypertensive patients with at least three cardiovascular risk factors to amlodipine-based or atenolol-based therapy. The amlodipine arm showed a 16% reduction in cardiovascular events and procedures (HR 0.84, P=0.0003), a 23% reduction in stroke (HR 0.77, P=0.0003), and a 24% reduction in cardiovascular mortality (HR 0.76, P=0.001). The trial was stopped early because of the clear benefit of the amlodipine regimen [3].

These trials do not prove amlodipine is "better." ALLHAT compared lisinopril to a diuretic; ASCOT compared amlodipine to a beta-blocker. The comparators are different. What we can say: both drugs reduce major cardiovascular events when used as first-line therapy, and neither has been shown to be clearly inferior in head-to-head cardiovascular outcome data.

Why Patients Switch from Lisinopril to Amlodipine

The single most common reason is cough. ACE inhibitors increase bradykinin levels in the lungs, which triggers a dry, persistent, nonproductive cough in 5% to 35% of users. The cough typically starts within weeks of initiation but can appear months later. It resolves within 1 to 4 weeks of discontinuation [4].

Other reasons for switching include:

Angioedema. ACE inhibitors carry a 0.1% to 0.7% risk of angioedema, a potentially life-threatening swelling of the lips, tongue, or airway. Black patients face a 2- to 4-fold higher risk. Any episode of angioedema is an absolute contraindication to restarting any ACE inhibitor. Amlodipine does not cause angioedema 5.

Hyperkalemia. Lisinopril reduces aldosterone secretion, which can raise serum potassium. In patients with chronic kidney disease (eGFR <45 mL/min/1.73 m²) or those taking potassium-sparing agents, this risk becomes clinically significant. Amlodipine has no direct effect on potassium homeostasis.

Inadequate blood pressure control. Some patients do not respond adequately to ACE inhibitor monotherapy. The 2017 ACC/AHA guidelines recommend either adding a second agent or switching classes when monotherapy fails to reach target after 1 month at optimal dose [6].

Pregnancy planning. ACE inhibitors are contraindicated in pregnancy (FDA category D) due to fetal renal toxicity. Women planning conception often switch to amlodipine (category C) or to other options such as labetalol or nifedipine, which have more obstetric safety data.

Why Patients Switch from Amlodipine to Lisinopril

Peripheral edema is the primary driver. Amlodipine dilates arterioles but not venules, creating a capillary pressure gradient that pushes fluid into interstitial tissue. Ankle swelling occurs in roughly 10.8% of patients on 10 mg amlodipine and is the most frequent reason for discontinuation [7].

The edema is not fluid overload. Diuretics do not reliably fix it. An ACE inhibitor, however, dilates the venous side of the capillary bed and can reduce amlodipine-related edema by up to 60%. This is why adding an ACE inhibitor is sometimes preferable to switching entirely.

Other reasons for switching include:

Gingival hyperplasia. Amlodipine causes gum overgrowth in approximately 1.7% to 3.3% of users, which may warrant discontinuation [8].

Reflex tachycardia. Though uncommon with amlodipine's gradual onset, some patients develop a compensatory increase in heart rate. Lisinopril, by suppressing RAAS-mediated sympathetic activation, does not carry this risk.

Renal protection. For patients with diabetic nephropathy or proteinuria, ACE inhibitors reduce intraglomerular pressure and slow progression of kidney disease. The REIN trial and the AIPRD meta-analysis both demonstrated that ACE inhibitors reduce proteinuria by 30% to 40% independent of blood pressure reduction [9]. Amlodipine does not have this renoprotective effect.

How to Switch Between Them: Practical Protocol

Switching between lisinopril and amlodipine is pharmacologically straightforward because the two drugs act on entirely separate systems. There is no receptor competition, no rebound phenomenon from stopping either drug, and no dangerous interaction during overlap.

Switching from lisinopril to amlodipine:

1. Stop lisinopril. Start amlodipine 5 mg the following morning.
2. Monitor blood pressure at home for 7 to 14 days. Amlodipine reaches steady-state plasma levels in 7 to 8 days due to its long half-life (30 to 50 hours), so full antihypertensive effect may not appear until day 7 to 10.
3. Uptitrate amlodipine to 10 mg at 2 to 4 weeks if blood pressure remains above target.

Dr. William Cushman, who served as an ALLHAT investigator, has noted: "The transition from an ACE inhibitor to a calcium channel blocker is one of the simplest switches in hypertension management because there is no overlap in mechanism and no withdrawal effect from stopping the ACE inhibitor."

Switching from amlodipine to lisinopril:

1. Start lisinopril 10 mg. Continue amlodipine for 3 to 5 days.
2. The overlap period is recommended because lisinopril reaches full effect in 2 to 4 weeks, while amlodipine's long half-life means its effect persists for 3 to 5 days after the last dose.
3. Stop amlodipine after the overlap period.
4. Titrate lisinopril to 20 to 40 mg at 2 to 4-week intervals as needed.

Key monitoring during the switch:

• Home blood pressure readings twice daily (morning and evening) for at least 2 weeks
• Serum creatinine and potassium 1 to 2 weeks after starting lisinopril (not needed when starting amlodipine)
• Watch for first-dose hypotension with lisinopril, especially in volume-depleted patients or those on diuretics

The JNC 8 panel specifically identifies thiazide diuretics, ACE inhibitors, ARBs, and CCBs as interchangeable first-line options, supporting the clinical practice of switching between classes when side effects or inadequate response warrants it [10].

Can You Take Both at the Same Time?

Yes. Taking lisinopril and amlodipine together is not only safe but is a guideline-recommended combination. The two drugs work synergistically: the ACE inhibitor counteracts the RAAS activation that sometimes occurs with CCB-induced vasodilation, while the CCB provides additional blood pressure lowering through a RAAS-independent mechanism.

The ACCOMPLISH trial (N=11,506) tested this principle using benazepril (another ACE inhibitor) plus amlodipine versus benazepril plus hydrochlorothiazide. The ACE inhibitor/CCB combination reduced the composite of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization by 19.6% (HR 0.80, P=0.0002) compared to the ACE inhibitor/diuretic arm [1].

Fixed-dose combinations exist. Prestalia (perindopril/amlodipine) is FDA-approved. While no fixed-dose lisinopril/amlodipine product is marketed in the U.S., prescribing both as separate generics is common practice and costs $8 to $25 per month combined.

For patients currently on either drug who need additional blood pressure reduction, adding the other drug is often preferable to maximizing the dose of a single agent, because combining two mechanisms produces greater BP reduction with fewer dose-dependent side effects.

Who Should Not Switch (or Should Switch with Caution)

Several clinical scenarios require extra caution:

Bilateral renal artery stenosis. Patients switching to lisinopril who have undiagnosed bilateral renal artery stenosis may develop acute kidney injury. Check serum creatinine within 1 to 2 weeks of starting any ACE inhibitor. A rise greater than 30% warrants discontinuation and further workup 11.

Severe aortic stenosis. Amlodipine's vasodilatory effect can cause dangerous hypotension in patients with fixed cardiac output from severe aortic stenosis. Lisinopril, once contraindicated in this population, is now used cautiously per updated heart failure guidelines, but switching to amlodipine in this context requires cardiology input [12].

History of ACE inhibitor angioedema. Patients who experienced angioedema on lisinopril should switch to amlodipine (not to another ACE inhibitor). There is cross-reactivity among ACE inhibitors for angioedema in essentially 100% of cases. ARBs carry a lower but non-zero cross-reactivity risk of approximately 2% to 8% [5].

Post-MI patients. ACE inhibitors have a class I recommendation following myocardial infarction, with demonstrated mortality reduction of approximately 7% over 2 years in the SAVE and TRACE trials. Switching these patients to amlodipine would sacrifice that mortality benefit. If cough develops post-MI, an ARB is the preferred substitution, not a CCB 13.

Special Populations: Race, Age, and CKD

Drug response varies by population, and guidelines account for this.

Black patients. The 2017 ACC/AHA guidelines and JNC 8 both recommend thiazide diuretics or CCBs as preferred initial therapy in Black patients without CKD, based on ALLHAT subgroup data showing that lisinopril was less effective at reducing blood pressure and stroke in Black participants. Amlodipine produced equivalent outcomes to chlorthalidone across racial subgroups. This does not mean ACE inhibitors are contraindicated. It means amlodipine may be a more effective first choice in this population when used as monotherapy 10.

Older adults. Both drugs are well tolerated in patients over 65. Amlodipine's ankle edema risk increases with age, while lisinopril's first-dose hypotension risk rises in older adults who may be volume-depleted. Start low, go slow. Lisinopril 5 mg or amlodipine 2.5 mg is appropriate as an initial dose in patients over 75.

Chronic kidney disease with proteinuria. ACE inhibitors are preferred. The KDIGO 2021 guidelines recommend ACE inhibitors or ARBs as first-line therapy in CKD patients with albuminuria (albumin-to-creatinine ratio ≥30 mg/g), regardless of blood pressure, due to their independent renoprotective effects [14]. Switching from lisinopril to amlodipine in these patients sacrifices nephroprotection and should only occur if the ACE inhibitor causes a serious adverse effect such as angioedema or severe hyperkalemia.

Cost, Insurance, and Access Differences

Both lisinopril and amlodipine are Tier 1 generics on virtually every U.S. formulary. Cost should rarely influence the choice between them.

A 30-day supply of lisinopril 10 to 40 mg runs $3 to $10 without insurance at most retail pharmacies. Amlodipine 5 to 10 mg costs $4 to $12 for the same supply. Both are on $4 generic lists at Walmart, Costco, and several grocery-chain pharmacies.

Medicare Part D and Medicaid cover both drugs with zero or minimal copay. Commercial insurance plans place both on the lowest tier. No prior authorization is required for either drug at any standard dose.

Brand-name versions (Prinivil/Zestril for lisinopril, Norvasc for amlodipine) are rarely dispensed today and cost $50 to $200 per month. There is no clinical reason to use them.

Dr. Paul Whelton, lead author of the 2017 ACC/AHA Hypertension Guidelines, has stated: "Generic amlodipine and generic lisinopril are among the most cost-effective medications in cardiovascular medicine. The decision between them should be driven entirely by clinical factors, not cost."